INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift
Source: SeekingAlpha
2025-08-08 15:24:14 ET
More on INmune Bio
- INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript
- INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's
- INmune Bio: Hold Rating Based On Path Forward Of XPro In Subset Of AD Patients
- INmune Bio gains as trial for prostate cancer therapy succeeds
- INmune Bio fails to meet main goal in Alzheimer's treatment study
Read the full article on Seeking Alpha
For further details see:
INmune Bio outlines CORDStrom BLA and MAA filings targeted for mid-2026 as CEO transition highlights strategic shift
INmune Bio Inc.
NASDAQ: INMB
INMB Trading
-3.93% G/L:
$1.59 Last:
342,332 Volume:
$1.66 Open:
INMB Latest News
May 15, 2026 08:00:00 am
INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro(TM) PlatformMay 14, 2026 08:00:00 am
INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's DiseaseINMB Stock Data
$100,001,939
20,608,626
3.69%
19
N/A
Biotechnology & Life Sciences
Healthcare
US
Boca Raton
